Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hypoxia-inducible factors activator, roxadustat, increases pulmonary vascular resistance in rats

T. Novák, M. Žaloudíková, P. Smolková, B. Kaftanová, J. Edlmanová, K. Krása, V. Hampl

. 2023 ; 72 (Suppl. 5) : S587-S592. [pub] 20231229

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24003897

Activators of hypoxia inducible factors (HIFs), such as roxadustat, are promising agents for anemia treatment. However, since HIFs are also involved in the regulation of the pulmonary circulation, we hypothesized that roxadustat increases pulmonary vascular resistance and vasoconstrictor reactivity. Using isolated, cell-free solution perfused rat lungs, we found perfusion pressure-flow curves to be shifted to higher pressures by 2 weeks of roxadustat treatment (10 mg/kg every other day), although not as much as by chronic hypoxic exposure. Vasoconstrictor reactivity to angiotensin II and acute hypoxic challenges was not altered by roxadustat. Since roxadustat may inhibit angiotensin-converting enzyme 2 (ACE2), we also tested a purported ACE2 activator, diminazene aceturate (DIZE, 0.1 mM). It produced paradoxical, unexplained pulmonary vasoconstriction. We conclude that the risk of serious pulmonary hypertension is not high when roxadustat is given for 14 days, but monitoring is advisable.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24003897
003      
CZ-PrNML
005      
20250409105522.0
007      
ta
008      
240305s2023 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.935220 $2 doi
035    __
$a (PubMed)38165762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Novák, Tomáš $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague 5, Czech Republic. vaclav.hampl@lfmotol.cuni.cz $7 xx0264348
245    10
$a Hypoxia-inducible factors activator, roxadustat, increases pulmonary vascular resistance in rats / $c T. Novák, M. Žaloudíková, P. Smolková, B. Kaftanová, J. Edlmanová, K. Krása, V. Hampl
520    9_
$a Activators of hypoxia inducible factors (HIFs), such as roxadustat, are promising agents for anemia treatment. However, since HIFs are also involved in the regulation of the pulmonary circulation, we hypothesized that roxadustat increases pulmonary vascular resistance and vasoconstrictor reactivity. Using isolated, cell-free solution perfused rat lungs, we found perfusion pressure-flow curves to be shifted to higher pressures by 2 weeks of roxadustat treatment (10 mg/kg every other day), although not as much as by chronic hypoxic exposure. Vasoconstrictor reactivity to angiotensin II and acute hypoxic challenges was not altered by roxadustat. Since roxadustat may inhibit angiotensin-converting enzyme 2 (ACE2), we also tested a purported ACE2 activator, diminazene aceturate (DIZE, 0.1 mM). It produced paradoxical, unexplained pulmonary vasoconstriction. We conclude that the risk of serious pulmonary hypertension is not high when roxadustat is given for 14 days, but monitoring is advisable.
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a zvířata $7 D000818
650    12
$a angiotensin konvertující enzym 2 $7 D000085962
650    _2
$a cévní rezistence $7 D014655
650    12
$a vazokonstriktory $x farmakologie $7 D014662
650    _2
$a hypoxie $x chemicky indukované $7 D000860
655    _2
$a časopisecké články $7 D016428
700    1_
$a Žaloudíková, Marie, $d 1971- $7 xx0206604 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Smolková, Pavlína $7 _AN122311 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kaftanová, Barbora, $d 1984- $7 xx0301775 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Edlmanová, Johana $7 _AN122312 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Krása, Kryštof $7 xx0301779 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
700    1_
$a Hampl, Václav, $d 1962- $7 nlk20030127352 $u Department of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, Suppl. 5 (2023), s. S587-S592
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38165762 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20240305 $b ABA008
991    __
$a 20250409105516 $b ABA008
999    __
$a ok $b bmc $g 2298736 $s 1213649
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c Suppl. 5 $d S587-S592 $e 20231229 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
LZP    __
$b NLK116 $a Pubmed-20240305

Najít záznam

Citační ukazatele

Možnosti archivace